Introduction
In an era where innovation drives the biotech landscape, Peptris has made a significant leap by securing ₹70 Cr in Series A funding. This infusion of capital marks a pivotal moment for the startup as it aims to enhance its artificial intelligence (AI)-led drug discovery platform. With an ambitious focus on accelerating preclinical drug development, Peptris is set to transform the future of pharmaceutical research.
Funding Impact
The latest funding round, co-led by IAN Alpha Fund and Speciale Invest, also saw contributions from Tenacity Ventures and BYT Ventures. The capital will be instrumental in expanding Peptris’s pipeline and advancing its programs toward clinical readiness. The startup envisions launching multiple new Novel Chemical Entities (NCE) and drug repurposing initiatives, breathing new life into clinical-stage drugs that were previously shelved.
Strategic Expansion
Peptris operates under a B2B model, collaborating with pharmaceutical and biotech firms, as well as select fast-moving consumer goods (FMCG) companies. The startup has set its sights on increasing its workforce, seeking talent across various domains including biology, chemistry, data science, and AI. Additionally, it plans to establish dedicated business development units in key markets like the US and Europe.
Innovative Technology
Founded in 2019 by Narayanan Venkatasubramanian, Shridhar Narayanan, Anand Budni, and Amit Mahajan, Peptris has crafted a proprietary platform that utilizes AI and machine learning to enhance drug discovery efficiency. The platform incorporates unsupervised learning and generative AI, enabling the design of optimized molecules tailored for therapeutic use.
Pipeline and Achievements
Peptris claims that its innovative platform has already led to the discovery of NCEs and the repurposing of approved drugs. Furthermore, it has successfully rescued molecules that demonstrated clinical safety. The startup boasts a robust pipeline of preclinical assets validated through both in vitro and in vivo disease models.
Operational Model
Operating virtually, Peptris emphasizes an AI-driven discovery process while outsourcing laboratory work to contract research organizations (CROs) and biotech partners. Its revenue streams are diversified, relying on licensing agreements, milestone payments, and royalties. Collaborative partnerships span academia, biotech, pharmaceutical companies, and organizations focused on rare diseases.
Industry Context
The demand for efficient drug discovery solutions is growing as traditional methods become economically unsustainable. Preclinical development costs have nearly doubled over the past nine years, prompting a shift towards technologies that enhance efficiency. IAN Alpha Fund’s managing partner, Rajnish Kapur, highlighted the transformative potential of AI in drug discovery, emphasizing its ability to streamline decision-making processes and reduce costs.
Government Support
The timing of this funding round aligns with a broader governmental push to invigorate the biotech sector. Finance Minister Nirmala Sitharaman recently introduced the “Biopharma SHAKTI” scheme, allocating ₹10,000 Cr over five years to foster research and innovation. This initiative, alongside the launch of the BIRAC–RDI Fund, underscores the Indian government’s commitment to scaling biotechnology innovations.
Competitive Landscape
As the biotech ecosystem flourishes, Peptris faces competition from other AI-driven drug discovery startups such as ImmunitoAI, Boltzmann, Medvolt, and AarogyaAI. However, the unique approach and technological advancements of Peptris position it favorably within this burgeoning market.
Conclusion
Peptris stands at the forefront of a transformative wave in drug discovery. With substantial funding and a commitment to innovation, the startup is poised to redefine the pharmaceutical landscape, offering hope for faster, more cost-effective solutions in the quest for new therapies. As it navigates this dynamic environment, Peptris exemplifies the potential of AI to reshape the future of healthcare.
- Key Takeaways:
- Peptris secured ₹70 Cr to enhance its AI-driven drug discovery platform.
- The startup plans to expand its pipeline and clinical readiness over the next two years.
- A focus on optimizing drug discovery processes positions Peptris favorably in a competitive market.
Read more → inc42.com